Mumbai : Fredun Pharmaceuticals Limited (BSE: FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products.

Q1 FY27 Standalone Financial Highlights

  • Total Income of ₹228.25 Cr, YoY growth of 90.44%
  • EBITDA of ₹32.78 Cr, YoY growth of 92.90%
  • EBITDA Margin (%) of 14.36%, YoY growth of 18 Bps
  • Net Profit of ₹13.17 Cr, YoY growth of 94.63%
  • Net Profit Margin (%) of 5.77%, YoY growth of 12 Bps
  • Basic EPS of ₹23.89, YoY growth of 66.71%

Commenting on the strong financial performance Mr. Fredun Medhora, Managing Director, said, “Q1 FY27 has set a strong tone for the year, with robust growth in both revenue and profitability. More importantly, the quarter reinforces our belief that the long-term investments we have made across the business are beginning to translate into tangible outcomes. It also validates the direction in which we have been building the Company over the last few years.

We have always believed in building the business with a long-term perspective. Our objective has never been to chase short-term growth, but to create a diversified healthcare company with multiple engines of growth. As we continue to expand our branded portfolio, enter newer healthcare categories and strengthen our manufacturing capabilities, we believe we are laying the foundation for the next phase of growth.

The opportunities ahead remain significant. Healthcare continues to evolve rapidly, creating demand for differentiated products, specialised therapies and preventive healthcare solutions. With the capabilities we have built and the strategic investments already in place, we remain optimistic about the future and committed to delivering sustainable growth while creating long-term value for our shareholders.”